Paper
0
Stromal Gene Signatures in Large-B-Cell Lymphomas
Authors
Georg Lenz,George Wright
Sandeep Davé,Wenming Xiao,John Powell,Hong Zhao,Weihong Xu,Bruce Tan,Neta Goldschmidt,Javeed Iqbal,Julie Vose,Martin Bast,Kai Fu,DD Weisenburger,Timothy Greiner,Jamés Armitage,Alastair Kyle,Lorraine May,Randy Gascoyne,Joseph Connors,Gunhild Trøen,Harald Holte,Stein Kvaløy,Daan Dierickx,Gregor Verhoef,Jan Delabie,Erlend Smeland,Pedro Jares,Antonio Martı́nez,Armando López‐Guillermo,Emili Montserrat,Elı́as Campo,Rita Braziel,Thomas Miller,Lisa Rimsza,James Cook,Brad Pohlman,John Sweetenham,Raymond Tubbs,Richard Fisher,Elena Hartmann,Andreas Rosenwald,German Ott,Müller-Hermelink Hk,David Wrench,T. Lister,Elaine Jaffe,Wyndham Wilson,Wing Chan
+47 authors
,Louis StaudtPublished
Nov 26, 2008
Show more
Save
Tip0
TipSave
Abstract
The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival of patients with diffuse large-B-cell lymphoma. Whether gene-expression signatures correlate with survival after treatment of diffuse large-B-cell lymphoma is unclear.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.